1 Improved resolution of influenza vaccination

2 responses with high-throughput live virus

3 microneutralisation

Lorin Adams^{*,1}, Phoebe Stevenson-Leggett^{*,2}, Jia Le Lee³, James Bazire², Giulia
Dowgier², Agnieszka Hobbs², Chloë Roustan⁴, Annabel Borg⁴, Christine Carr¹, Silvia
Innocentin³, Louise MC Webb³, Callie Smith⁴, Philip Bawumia⁴, Nicola Lewis¹, Nicola
O'Reilly⁴, Svend Kjaer⁴, Michelle A Linterman³, Ruth Harvey^{*,1}, Mary Y Wu^{*,2}, and
Edward J Carr^{*,4,5,**}

- ⁹ ^{*} These authors contributed equally to this work.
- ¹ Worldwide Influenza Centre, The Francis Crick Institute, 1 Midland Road, London NW1 1AT,
- 11 UK
- 12 ² COVID Surveillance Unit, The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
- ³ Immunology Program, Babraham Institute, Cambridge, UK
- ⁴ The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK
- ⁵ UCL Centre for Kidney & Bladder Health, Royal Free Hospital, Rowland Hill Street, London
- 16 NW3 2PF, UK
- 17 Correspondence: Edward J Carr <edward.carr@ucl.ac.uk>
- 18 Word count 2502
- 19

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

20 Abstract

21 Influenza remains a significant threat to human and animal health. Assessing serological 22 protection against influenza has relied upon haemagglutinin inhibition assays, which are used to 23 gauge existing immune landscapes, seasonal vaccine decisions and in systems vaccinology 24 studies. Here, we adapt our high-throughput live virus microneutralisation assay for SARS-CoV-25 2, benchmark against haemagglutinin inhibition assays, and report serological vaccine 26 responsiveness in a cohort of older (>65yo) community dwelling adults (n=73), after the 27 adjuvanted 2021-22 Northern Hemisphere quadrivalent vaccine. We performed both assays 28 against all four viruses represented in the vaccine (A/Cambodia/H3N2/2020, 29 A/H1pdm/Victoria/2570/2019, B/Yamagata/Phuket/2013, BVIC/Washington/02/2019), using 30 sera drawn on days 0 [range: d-28 to d0], 7 [d6-10] and 182 [d161-196] with respect to 31 vaccination. We found population-level concordance between the two assavs (Spearman's 32 correlation coefficient range 0.48-0.88; all $P \le 1.4 \times 10^{-5}$). The improved granularity of 33 microneutralisation was better able to estimate fold-changes of responses, and quantify the 34 inhibitory effect of pre-existing antibody. Our high-throughput method offers an alternative 35 approach to assess influenza-specific serological responses with improved resolution.

36 Introduction

37 Influenza causes an estimated 389,000 deaths a year (1). Whilst annually updated multi-valent 38 vaccines reduce this burden, better laboratory methods offering rapid, granular evaluation of the 39 neutralising antibody response to these vaccines could further minimise this. Firstly, by 40 facilitating refined yearly strain selection through high resolution quantification of the pre-existing 41 antibody landscape. Secondly, by rapid, robust comparison between vaccine platforms, both 42 existing (protein, adjuvanted protein, live-attenuated virus, or split virion), and upcoming (mRNA, 43 and others). Thirdly, by providing a continuous response variable for systems vaccinology 44 studies, to better leverage multi-modal high-dimensional and longitudinal datasets, themselves

Page 2 of 17

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

| 45 | generated at significant cost and resource. Finally, by allowing prompt re-evaluation of human |
|----|--|
| 46 | population immunity when an antigenically shifted influenza virus emerges, such as H5N1. |
| 47 | Currently, the haemagglutinin inhibition (HAI) assay is used to evaluate existing population-level |
| 48 | immunity to guide annual vaccine strain selection, to confirm immunogenicity of these updated |
| 49 | preparations, and as a correlate of protection. HAI assays are largely unchanged since first |
| 50 | described in the 1940s (2,3): they are scalable, require minimal specialist laboratory equipment, |
| 51 | but do not directly measure neutralising antibody, a critical effector arm of immunity. Virus will |
| 52 | agglutinate red blood cells, naturally decorated with sialic acid, the ligand for influenza's HA. |
| 53 | Agglutination is inhibited by sera containing HA-specific antibodies. Live-virus neutralisation |
| 54 | assays for influenza have existed for decades (4), but have to-date not been capable of |
| 55 | displacing the HAI assay, largely due to limitations in the number of sera processed and their |
| 56 | relative complexity. |

57 Results and Discussion

58 Here, we perform a head-to-head comparison of paired HAI, and a newly developed high-59 throughput live-virus microneutralisation (LV-N) assay. We demonstrate that large scale 60 microneutralisation assays (see Materials and Methods) of 4 influenza strains are both feasible. 61 and offer enhanced resolution. Adapting our SARS-CoV-2 approach, retains a similar 62 throughput of ~1,000-1,500 sera for 3 strains per week. We report sera from the AgeVAX study. 63 an observational study of influenza vaccine responses in 73 community dwelling older adults 64 (>65yo), with venepuncture on days 0 [range: d-28 to d0], 7 [d6-10] and 182 [d161-196] post-65 vaccination (Table 1, Fig 1A).

66 We first confirm increased antibody titres for all 4 influenza strains at d7 after administration of

67 the 2021-22 vaccine using HAI (d7 vs d0 Wilcoxon P<0.015 for all strains, Fig 1B). Between

68 paired sera, we find waning from d7 to d182 for two of the four immunised strains

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

| 69 | (A/Cambodia/H3N2/2020 <i>P</i> =0.19; A/H1pdm/Victoria/2570/2019 <i>P</i> =6.1×10 ⁻⁴ ; |
|----|--|
| 70 | B/Yamagata/Phuket/2013 <i>P</i> =0.16; BVIC/Washington/02/2019 <i>P</i> =0.024, <u>Fig 1B</u>). We next |
| 71 | repeated this immunogenicity assessment using our newly developed LV-N assay (Fig 1C). The |
| 72 | boosting effect of vaccination is, once again, clear (d7 vs d0 <i>P</i> <0.002 for all strains, <u>Fig 1C</u>). |
| 73 | With the LV-N assay, three of the four immunised strains showed significant waning between d7 |
| 74 | and d182 A/Cambodia/H3N2/2020 <i>P</i> =0.4; A/H1pdm/Victoria/2570/2019 <i>P</i> =2.8×10 ⁻⁴ ; |
| 75 | B/Yamagata/Phuket/2013 P=0.004; BVIC/Washington/02/2019 P=2.9×10 ⁻⁴ . The quantitative |
| 76 | nature of the LV-N assays offers improved resolution of the fold-change of the acute response |
| 77 | (in the AgeVax study, the fold-change in titres d7/d0), with geometric mean fold-changes [95% |
| 78 | confidence intervals] for LV-N estimating smaller reductions boosts with less uncertainty |
| 79 | between these visits, when compared with HAI (Fig 1D). Furthermore, the waning (d182/d7) of |
| 80 | B/Yamagata reached statistical significance only within the LV-N dataset (Figs 1B & 1C). |
| 81 | Thirdly, we plotted pairwise comparisons between HAI and LV-N for each strain at each of the |
| 82 | three venepuncture visits (Fig 2A). Overall, the two assays showed a strong positive correlation |
| 83 | according to their Spearman's correlation coefficients. Considering differences between strains, |
| 84 | B/Yamagata showed relatively weaker correlations than the other 3 strains. Next, considering |
| 85 | differences over the 3 timepoints, the between-assay correlation for B/Victoria was weakest at |
| 86 | d182, but no other strains showed marked differences over time. |
| 07 | Despite the bight concerdence between energy at a negative level we noted that for a since |
| 87 | Despite the high concordance between assays at a population-level, we noted that for a given |
| 88 | HAI titre, the range of corresponding LV-N results was large: for example, an HAI titre of 20 at |
| 89 | baseline (d0) corresponded to an LV-N range of 43-1004 for influenza A/H1. This 23-fold |
| 90 | difference suggests that immunologically important differences in vaccine responses are |

- 91 aggregrated into discrete HAI values. To address the question of whether LV-N offered
- 92 improved sensitivity for biologically relevant heterogeneity over HAI, we returned to the
- 93 observation that pre-existing antibody limits the fold-induction of antibody after vaccination (5).

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

94 Using HAI, we found that we could observe this negative relationship between higher baseline 95 titres and lower fold-changes (d7/d0) for only FluA/H1pdm (P=0.029), with the other strains 96 showing non-significant trends (**Fig 3A**). Repeating this comparison with LV-N, we found 97 moderately strong negative correlations between pre-existing neutralising antibody and peak 98 fold-change (d7/d0) for all variants (all P<0.009, **Fig 3B**). Coupling longitudinal LV-N-derived 99 serological data with multi-modal datasets promises to unlock new potentials in systems 910 vaccination, examining both peak and waned responses.

101 There are some limitations to our study. This single centre study enrolled older healthy adults, 102 likely to mount a memory response, recalling both previously haemagglutinin-experienced B 103 cells and recruiting naive B cells. It is plausible that a primary influenza vaccine response might 104 be alternatively performant between these assays, particularly if significant IgM is produced, 105 likely to perform well at HAI. Additionally, our live-virus microneutralisation approach reflects 106 serological neutralisation of both HA and neuraminidase, whereas HAI does not assay NA-107 directed neutralisation. Other implementations of microneutralisation assays use alternative 108 readouts for infection: for example, the WHO protocol uses an ELISA for nucleoprotein on fixed 109 MDCK cells (reporting the lowest dilution at which the OD405 is below the midpoint of OD405 of 110 virus-only and cell-only controls) (6), and a recently described next-generation sequencing 111 assay testing infectivity/neutralisation of many DNA-barcoded viruses in parallel (7). Whilst, we 112 have not directly compared with these methods, the DNA-barcoding approach can only find HA-113 related neutralisation, and the WHO neutralisation assay reports discrete rather than continuous 114 data.

In summary, we have shown that high-throughput live-virus microneutralisation assays are noninferior to HAI with strong correlations at population-levels. Further, we find that the continuous titre values returned by LV-N allow for finer dissection of vaccine responses, that are obfuscated by HAI. High-throughput influenza LV-N therefore has the potential to be a catalyst for rapid,

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

- robust assessment of existing antibody landscapes, new vaccine strain formulations, a step-
- 120 change in systems vaccinology, and a facet of laboratory-based pandemic preparedness.

121 Materials and Methods

122 Study design, serum collection and ethics

- 123 The immune responses to vaccines in older persons study (AgeVax) enrolled community
- 124 dwelling older adults already enrolled within the NIHR Cambridge BioResource to assess their
- response to seasonal influenza vaccine. AgeVax was approved by the Yorkshire & The Humber
- South Yorkshire Research Ethics Committee (IRAS 277259, REC 20/YH/0101), and
- 127 sponsored by the Babraham Institute, Cambridge. Healthy participants were enrolled if they
- 128 were planning to receive the seasonal influenza vaccine as part of their routine care (in the UK,
- 129 influenza vaccine is offered to all >65yo), were able to attend for consenting and venepuncture,
- and carried at least 1 allele of *HLADR**0701, *HLADR**0401 or *HLADR**1101 (determined by
- 131 single nucleotide polymorphism typing using the UK Biobank v2.1 Axiom array). Controlled
- 132 comorbidities such as hypertension or hypercholesterolaemia were not exclusion criteria.
- 133 Concomitant medications and comorbidities are not available for research purposes.
- 134 Venepuncture was performed up to 28 days pre-vaccination and on days 6-10, and 161-196
- 135 post vaccination. All participants received the adjuvanted quadrivalent influenza vaccine
- 136 (Seqirus UK Ltd) via intramuscular injection. Blood was collected into silica-coated serum tubes
- 137 and centrifuged at 2000rpm for 5 minutes and stored in aliquots at -80C. These sera were
- 138 provided to the Francis Crick Institute for influenza assays described below.

139 Cells and viruses

- 140 MDCK cells expressing the SIAT1 gene (MDCK-SIAT1) were maintained under selection in
- 141 DMEM containing 1mg/ml Geneticin (G418) Sulphate (Stratech Scientific APE2513) and 1%

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

- 142 Penicillin/Streptomycin (Sigma-Aldrich). Cells were seeded in DMEM containing 1%
- 143 Penicillin/Streptomycin into 384-well cell culture microplates (Griener Bio-One Ltd) 18-20 hours
- 144 prior to use in live-virus microneutralisation assays.
- 145 All influenza virus isolates used in this study were propagated in the allantoic cavity of 10-day-
- 146 old embryonated hens' eggs at 35°C for 48 hours.

147 Hemagglutinin inhibition assays for influenza

- 148 Haemagglutination and haemagglutinin inhibition (HAI) assays were performed according to
- 149 standard methods using suspensions of guinea pig RBCs (1.0% v/v) for A(H3N2) viruses and
- 150 turkey RBCs (0.75% v/v) for A(H1N1)pdm09 and type B viruses with all serum samples pre-
- 151 treated with receptor-destroying enzyme (RDE) from Vibrio cholera (8). Four haemagglutination
- 152 units were used in all HAI assays. For A(H3N2) viruses, haemagglutination and HAI assays
- 153 were conducted in the presence of 20 nM oseltamivir carboxylate (9).

154 Live-virus microneutralisation assays for influenza

- 155 To perform high-throughput live virus microneutralisation assays for influenza we adapted our
- existing approach for SARS-CoV-2 neutralisation (10–12). MDCK-SIAT1 cells at 80%
- 157 confluency were infected with selected influenza isolates in 384-well format, in the presence of
- 158 10-fold serial dilutions of participant serum samples, diluted in DMEM containing 1%
- 159 Penicillin/Streptomycin. After 24 hours incubation at 37°C, cells were fixed using 4%
- 160 formaldehyde (v/v), permeabilised with 0.2% TritonX-100 with 3% BSA in PBS (v/v), and stained
- 161 for Influenza nucleoprotein (NP) using Biotin-labelled-clone-2-8C antibody produced in-house in
- 162 conjunction with an Alexa488-Streptavidin (Invitrogen S32354) for influenza A isolates, or the
- 163 mouse monoclonal B017 (Abcam, ab20711) in conjunction with an Alexa488 conjugated Goat
- anti-Mouse secondary (ThermoFisher, A21141) for influenza B isolates. Cellular DNA was
- stained using DAPI. Whole-well imaging at 5x magnification was carried out using an Opera

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

| 166 | Phenix (Perkin Elmer) and fluorescent areas calculated using the Phenix-associated software |
|--|--|
| 167 | Harmony (Perkin Elmer). Virus inhibition by patient serum samples was estimated from the |
| 168 | measured area of infected cells/total area occupied by all cells in each well and then expressed |
| 169 | as percentage of maximal (virus only control wells). Infected cells were identified by presence of |
| 170 | Influenza NP staining. The inhibitory profile of each serum sample was estimated by fitting a 4- |
| 171 | parameter dose response curve executed in SciPy. Neutralising antibody titres are reported as |
| 172 | the fold-dilution of serum required to inhibit 50% of viral replication (IC_{50}), and are further |
| 173 | annotated if they lie above the quantitative range (>40,000), below the quantitative range (<40) |
| 174 | but still within the qualitative range (i.e. partial inhibition is observed but a dose-response curve |
| 175 | cannot be fitted because it does not sufficiently span the IC_{50}), or if they show no inhibition at all. |
| 176 | Viral isolates used in this study: A/Cambodia/e0826360/2020 H3N2, IVR-215 |
| 177 | (A/Victoria/2570/2019) H1pdm, B/Phuket/3073/2013, B/Washington/02/2019. |
| | |
| 178 | Data curation and analyses |
| 178 179 | Data curation and analyses |
| 178 179 180 | Data curation and analyses HAI and live-virus microneutralisation titres were associated with anonymized metadata using R (y 4 2 2) and <i>tidyverse</i> $(y 1 3 2) (13)$ Plots were generated using <i>agplot2</i> $(y 3 4 2)$ with |
| 178 179 180 181 | Data curation and analyses HAI and live-virus microneutralisation titres were associated with anonymized metadata using R (v 4.2.2) and <i>tidyverse</i> (v 1.3.2) (13). Plots were generated using <i>ggplot2</i> (v 3.4.2), with <i>stat_summary</i> () to add geometric means or medians, as indicated in the figure legends. To plot |
| 178 179 180 181 | Data curation and analyses HAI and live-virus microneutralisation titres were associated with anonymized metadata using R (v 4.2.2) and <i>tidyverse</i> (v 1.3.2) (13). Plots were generated using <i>ggplot2</i> (v 3.4.2), with <i>stat_summary()</i> to add geometric means or medians, as indicated in the figure legends. To plot |
| 178 179 180 181 182 | Data curation and analyses HAI and live-virus microneutralisation titres were associated with anonymized metadata using R (v 4.2.2) and <i>tidyverse</i> (v 1.3.2) (13). Plots were generated using <i>ggplot2</i> (v 3.4.2), with <i>stat_summary()</i> to add geometric means or medians, as indicated in the figure legends. To plot HAI titres, sera with no inhibition were re-coded as 2.5. To plot LV-N titres, sera with either no |
| 178 179 180 181 182 183 | Data curation and analyses HAI and live-virus microneutralisation titres were associated with anonymized metadata using R (v 4.2.2) and <i>tidyverse</i> (v 1.3.2) (13). Plots were generated using <i>ggplot2</i> (v 3.4.2), with <i>stat_summary()</i> to add geometric means or medians, as indicated in the figure legends. To plot HAI titres, sera with no inhibition were re-coded as 2.5. To plot LV-N titres, sera with either no inhibition of viral entry, or qualitative inhibition below the quantitative range (40-40,000), or |
| 178 179 180 181 182 183 184 | Data curation and analyses HAI and live-virus microneutralisation titres were associated with anonymized metadata using R (v 4.2.2) and <i>tidyverse</i> (v 1.3.2) (13). Plots were generated using <i>ggplot2</i> (v 3.4.2), with <i>stat_summary()</i> to add geometric means or medians, as indicated in the figure legends. To plot HAI titres, sera with no inhibition were re-coded as 2.5. To plot LV-N titres, sera with either no inhibition of viral entry, or qualitative inhibition below the quantitative range (40-40,000), or inhibition greater than the quantitative range were re-coded as 5, 10 or 80,000 respectively. HAI |
| 178 179 180 181 182 183 184 185 | Data curation and analyses HAI and live-virus microneutralisation titres were associated with anonymized metadata using R (v 4.2.2) and <i>tidyverse</i> (v 1.3.2) (13). Plots were generated using <i>ggplot2</i> (v 3.4.2), with <i>stat_summary()</i> to add geometric means or medians, as indicated in the figure legends. To plot HAI titres, sera with no inhibition were re-coded as 2.5. To plot LV-N titres, sera with either no inhibition of viral entry, or qualitative inhibition below the quantitative range (40-40,000), or inhibition greater than the quantitative range were re-coded as 5, 10 or 80,000 respectively. HAI and LV-N results were compared using two-tailed paired Wilcoxon tests, as implemented in the |
| 178 179 180 181 182 183 184 185 186 | Data curation and analyses HAI and live-virus microneutralisation titres were associated with anonymized metadata using R (v 4.2.2) and <i>tidyverse</i> (v 1.3.2) (13). Plots were generated using <i>ggplot2</i> (v 3.4.2), with <i>stat_summary()</i> to add geometric means or medians, as indicated in the figure legends. To plot HAI titres, sera with no inhibition were re-coded as 2.5. To plot LV-N titres, sera with either no inhibition of viral entry, or qualitative inhibition below the quantitative range (40-40,000), or inhibition greater than the quantitative range were re-coded as 5, 10 or 80,000 respectively. HAI and LV-N results were compared using two-tailed paired Wilcoxon tests, as implemented in the <i>rstatix</i> package, and resulting P values were plotted <i>ggpubr::geom_bracket()</i> and |
| 178 179 180 181 182 183 184 185 186 187 | Data curation and analyses HAI and live-virus microneutralisation titres were associated with anonymized metadata using R (v 4.2.2) and <i>tidyverse</i> (v 1.3.2) (13). Plots were generated using <i>ggplot2</i> (v 3.4.2), with <i>stat_summary(</i>) to add geometric means or medians, as indicated in the figure legends. To plot HAI titres, sera with no inhibition were re-coded as 2.5. To plot LV-N titres, sera with either no inhibition of viral entry, or qualitative inhibition below the quantitative range (40-40,000), or inhibition greater than the quantitative range were re-coded as 5, 10 or 80,000 respectively. HAI and LV-N results were compared using two-tailed paired Wilcoxon tests, as implemented in the <i>rstatix</i> package, and resulting P values were plotted <i>ggpubr::geom_bracket(</i>) and <i>ggtext::geom_richtext(</i>). Bias corrected 95% confidence intervals for fold-changes in HAI and |
| 178 179 180 181 182 183 184 185 186 187 188 | Data curation and analysesHAI and live-virus microneutralisation titres were associated with anonymized metadata using R(v 4.2.2) and tidyverse (v 1.3.2) (13). Plots were generated using ggplot2 (v 3.4.2), withstat_summary() to add geometric means or medians, as indicated in the figure legends. To plotHAI titres, sera with no inhibition were re-coded as 2.5. To plot LV-N titres, sera with either noinhibition of viral entry, or qualitative inhibition below the quantitative range (40-40,000), orinhibition greater than the quantitative range were re-coded as 5, 10 or 80,000 respectively. HAIand LV-N results were compared using two-tailed paired Wilcoxon tests, as implemented in therstatix package, and resulting P values were plotted ggpubr::geom_bracket() andggtext::geom_richtext(). Bias corrected 95% confidence intervals for fold-changes in HAI andLV-N were calculated from 1000 bootstraps generated with the infer package (14). For |
| 178 179 180 181 182 183 184 185 186 187 188 189 | Data curation and analysesHAI and live-virus microneutralisation titres were associated with anonymized metadata using R(v 4.2.2) and tidyverse (v 1.3.2) (13). Plots were generated using ggplot2 (v 3.4.2), withstat_summary() to add geometric means or medians, as indicated in the figure legends. To plotHAI titres, sera with no inhibition were re-coded as 2.5. To plot LV-N titres, sera with either noinhibition of viral entry, or qualitative inhibition below the quantitative range (40-40,000), orinhibition greater than the quantitative range were re-coded as 5, 10 or 80,000 respectively. HAIand LV-N results were compared using two-tailed paired Wilcoxon tests, as implemented in therstatix package, and resulting P values were plotted ggpubr::geom_bracket() andggtext::geom_richtext(). Bias corrected 95% confidence intervals for fold-changes in HAI andLV-N were calculated from 1000 bootstraps generated with the infer package (14). Forcorrelation between HAI and LV-N, Spearman's correlation was used without censoring data |

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

above or below the quantitative ranges of HAI or LV-N. Anonymised data and R code are freely
available via github:https://github.com/EdjCarr/AgeVax_HAI_LVN

192 Acknowledgements

193 The NIHR Cambridge Biomedical Research Center (BRC) is a partnership between Cambridge

- 194 University Hospitals NHS Foundation Trust and the University of Cambridge, funded by the
- 195 National Institute for Health Research (NIHR). We thank all NIHR Cambridge BRC volunteers
- 196 for their participation and thank the NIHR Cambridge BRC staff for their contribution in
- 197 coordinating the vaccinations and venepuncture. We would like to thank Marna Roos, Gita
- 198 Mistry, Nicola Bex, Natasha Bowyer Irvine at the Francis Crick Institute and Heather Bath at the
- Babraham Institute. MAL is a Lister Institute Prize Fellow. EJC is supported by a Medical
- 200 Research Council Clinician Scientist Fellowship (MR/X006751/1). This work was supported by
- 201 the NIHR Cambridge BRC, the Dunhill Medical Trust (RPGF1910/223 to MAL), the
- 202 Biotechnology and Biological Sciences Research Council (BBS/E/B/000C0427,
- BBS/E/B/000C0428, and the Campus Capability Core Grant to the Babraham Institute), the
- 204 Medical Research Council (MR/X006751/1 to EJC), a UKRI Frontier award (EP/X022382/1 to
- 205 MAL), in part funded by the NIH Centres of Excellence in Influenza Research and Response
- program Penn-CEIRR contract (75N93021C00015), and by the Francis Crick Institute which
- receives its core funding from Cancer Research UK (CC1114, CC2230, CC0102), the UK
- 208 Medical Research Council (CC1114, CC2230, CC0102), and the Wellcome Trust (CC1114,
- 209 CC2230, CC0102). The co-first and co-last authors contributed equally and are at liberty to list
- 210 these authorships in any order on their curriculum vitae.

211 Author contributions

- 212 LA: Conceptualization, Methodology, Investigation
- 213 PSL: Conceptualization, Methodology, Investigation

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

- 214 JLL: Project administration, Methodology, Investigation
- 215 JB: Methodology, Investigation
- 216 GD: Methodology, Investigation
- 217 AH: Methodology, Investigation
- 218 CR: Resources
- 219 AB: Resources
- 220 CC: Resources
- 221 SI: Methodology, Investigation
- 222 LMCW: Methodology, Investigation
- 223 CS: Resources
- 224 PB: Resources
- 225 NL: Resources, Supervision
- 226 NO'R: Resources, Supervision
- 227 SK: Resources, Supervision
- 228 MAL: Conceptualization, Funding acquisition, Supervision, Writing review & editing
- 229 RH: Conceptualization, Funding acquisition, Investigation, Supervision, Writing review &
- 230 editing
- 231 MYW: Conceptualization, Funding acquisition, Investigation, Supervision, Writing review &
- 232 editing

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

- 233 EJC: Conceptualization, Data Curation, Formal Analysis, Visualisation, Writing original draft, ,
- 234 Writing review & editing

235 Role of the funding source

- 236 The funders of the study had no role in study design, data collection, data analysis, data
- 237 interpretation, or writing of the report. The corresponding authors had full access to all the data
- and the final responsibility to submit for publication.

239 **Declaration of interests**

All authors declare no competing interests.

241 **References**

- 242 1. Paget J, Spreeuwenberg P, Charu V, Taylor RJ, Iuliano AD, Bresee J, et al.
- 243 Global mortality associated with seasonal influenza epidemics: New burden estimates

244 and predictors from the GLaMOR Project. Journal of Global Health. 2019

- 245 Dec;9(2):020421.
- 246 2. Salk JE. A Simplified Procedure for Titrating Hemagglutinating Capacity of
- 247 Influenza-Virus and the Corresponding Antibody. The Journal of Immunology [Internet].
- 248 1944 Aug 1;49(2):87–98. Available from:
- 249 https://journals.aai.org/jimmunol/article/49/2/87/100144/A-Simplified-Procedure-for-
- 250 Titrating

251 3. Hirst GK. THE QUANTITATIVE DETERMINATION OF INFLUENZA VIRUS AND

252 ANTIBODIES BY MEANS OF RED CELL AGGLUTINATION. The Journal of

- 253 Experimental Medicine. 1942 Jan 1;75(1):49–64.
- Bachmann MF, Ecabert B, Kopf M. Influenza virus: a novel method to assess
 viral and neutralizing antibody titers in vitro. Journal of Immunological Methods. 1999
 May 27;225(1-2):105–11.

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

- 5. Tsang JS, Schwartzberg PL, Kotliarov Y, Biancotto A, Xie Z, Germain RN, et al.
- 258 Global analyses of human immune variation reveal baseline predictors of
- 259 postvaccination responses. Cell. 2014 Apr 10;157(2):499–513.
- 260 6. World Health Organization. SEROLOGICAL DIAGNOSIS OF INFLUENZA BY
- 261 MICRONEUTRALIZATION ASSAY. 2010; Available from:
- 262 https://www.who.int/publications/i/item/serological-diagnosis-of-influenza-by-
- 263 microneutralization-assay
- 264 7. Loes AN, Tarabi RAL, Huddleston J, Touyon L, Wong SS, Cheng SMS, et al.

265 High-throughput sequencing-based neutralization assay reveals how repeated

266 vaccinations impact titers to recent human H1N1 influenza strains. bioRxiv: The Preprint

- 267 Server for Biology. 2024 Mar 9;2024.03.08.584176.
- 8. World Health Organization. Manual for the laboratory diagnosis and virological
 surveillance of influenza. WHO global influenza surveillance network: manual for the
 laboratory diagnosis and virological surveillance of influenza [Internet]. 2011; Available
 from: https://iris.who.int/handle/10665/44518
- 272 9. Lin YP, Gregory V, Collins P, Kloess J, Wharton S, Cattle N, et al.
- 273 Neuraminidase receptor binding variants of human influenza A(H3N2) viruses resulting
- 274 from substitution of aspartic acid 151 in the catalytic site: a role in virus attachment?
- 275 Journal of Virology. 2010 Jul;84(13):6769–81.
- 276 10. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, et al. AZD1222-
- 277 induced neutralising antibody activity against SARS-CoV-2 Delta VOC. Lancet (London,
- 278 England). 2021 Jul 17;398(10296):207–9.
- 279 11. Carr EJ, Dowgier G, Greenwood D, Herman LS, Hobbs A, Ragno M, et al.
- 280 SARS-CoV-2 mucosal neutralising immunity after vaccination. The Lancet Infectious
- 281 Diseases. 2023 Dec 6;
- 282 12. Shawe-Taylor M, Greenwood D, Hobbs A, Dowgier G, Penn R, Sanderson T, et
- al. Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster
- 284 campaign. Lancet (London, England). 2024 Mar 11;

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

- 285 13. Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, et al.
- Welcome to the tidyverse. Journal of Open Source Software [Internet]. 2019 Nov
- 287 21;4(43):1686. Available from: http://dx.doi.org/10.21105/joss.01686
- 288 14. Couch S, Bray A, Ismay C, Chasnovski E, Baumer B, Çetinkaya-Rundel M. Infer:
- 289 An r package for tidyverse-friendly statistical inference. Journal of Open Source
- 290 Software [Internet]. 2021 Sep 16;6(65):3661. Available from:
- 291 https://joss.theoj.org/papers/10.21105/joss.03661

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS



Fig 1. Serological vaccination responses quantified by haemagglutinin inhibition and high-throughput live influenza neutralisation assays in the AgeVax study (A)

AgeVax study design 73 individuals >65yo were vaccinated with adjuvanted quadrivalent influenza vaccine in the 2021-22 Northern Hemisphere season. (**B & C**) Haemagglutinin inhibition assay titres (HAI, **B**) or live-virus microneutralisation assay titres (LV-N, **C**), expressed as the reciprocal of the dilution at which 50% of virus infection is inhibited (IC₅₀), at baseline (d0), and days 7 and 182 after vaccination (d7 & d182, respectively) for the flu viruses listed. (**D**) Log₂ fold changes for peak (d7/d0) and wane (d182/d7) response as measured by HAI or LV-N (plotted as squares or circles respectively). Bootstrapped 95% confidence intervals are shown. In (B & C), crosses indicate geometric means, and *P* values from 2-tailed paired Wilcoxon signed rank tests are shown. In (C), diamonds indicate medians.

It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS





It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS





It is made available under a CC-BY 4.0 International license .

influenza HAI vs HTS

296 Table 1

| Characteristic | AgeVAX , N = 73 ¹ |
|----------------|-------------------------------------|
| Age | 70.0 [68.0-74.0] |
| Sex | |
| F | 35 (48%) |
| М | 38 (52%) |

¹Median [25%-75%]; n (%)